Novo Nordisk will continue to restrict United States supplies of starter doses of its hugely popular Wegovy weight-loss drug, as the company struggles to keep up with soaring US demand
Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File PhotoWegovy flying off the shelves in U.S.
The news came as the Danish drugmaker raised its full-year profit and sales forecasts for a second time., is riding a wave of sky-high demand for its highly effective diabetes and weight-loss drugs Ozempic and Wegovy, which has sent earnings and shares to record highs. The company said it would extend the limits introduced for Wegovy supplies, having said in May that it wouldsupply of starter doses to the U.S. market for several months to ensure supplies for existing patients.
More than 650 million adults worldwide are obese and a further 1.3 billion are overweight, exacerbating conditions such as heart disease and diabetes, the World Health Organization says.its earnings guidance in April, Novo now expects 2023 operating profit growth in local currencies of between 31% and 37% on sales growth of 27-33%. The new outlook is up from previous estimates of 24-30% and 28-34% respectively.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial showsResults of a late-stage drug trial conducted by Novo Nordisk show that weight loss drug Wegovy can reduce the risk of heart disease in certain patients. Wegovy was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and weight-related conditions.
Read more »
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Read more »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Read more »
Novo's Wegovy Shows Heart Benefit Alongside Weight Loss in TrialNovo Nordisk, the maker of Wegovy, announced that a large study has demonstrated the cardiovascular benefits of the highly effective obesity treatment. This finding is significant as it allows the Danish company to expand its market beyond being perceived as a lifestyle drug. The positive results from the trial may also encourage insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy for a wider range of patients.
Read more »
Morgan Stanley predicts Eli Lilly shares to rally on Novo's obesity drug dataMorgan Stanley believes that the positive data on Novo Nordisk's obesity drug Wegovy will also benefit Eli Lilly, leading to a potential increase in its stock value. Novo Nordisk's shares surged by 15% following the release of late-stage trial data, which demonstrated that Wegovy reduced the risk of major cardiovascular events by 20% compared to a placebo.
Read more »
Stocks making the biggest moves premarket: UPS, Lucid, Beyond Meat, Novo Nordisk and moreChegg shares surge over 20% after beating revenue expectations and announcing AI-focused strategies integration.
Read more »